Best Options Strategy for BBIO
Looking for the best options strategy for BridgeBio Pharma, Inc. (BBIO)? There is no single answer — the right play depends on your outlook, your risk tolerance and current implied volatility. Below, our free engine shows the highest-scoring defined-risk strategy on the live BBIO option chain right now, and a simple map from your view on BBIO to the strategy that fits it. Model any of them in the calculator before you trade.
About BBIO
BridgeBio Pharma, Inc. (BBIO) is a major company in Biotechnology. Options traders on BBIO tend to watch , since these can drive large moves in the share price.
About BridgeBio Pharma, Inc.
BridgeBio Pharma develops and commercializes medicines targeting genetic diseases, with a pipeline spanning small molecule drugs, gene therapies, and other modalities. The company's marketed product Attruby treats a form of heart amyloidosis by stabilizing the transthyretin protein, while Nulibry addresses molybdenum cofactor deficiency through synthetic enzyme replacement. Its clinical-stage candidates include infigratinib for growth disorders in children, encaleret for calcium regulation disorders, and several investigational therapies for muscular dystrophy and neurological conditions like Canavan disease. BridgeBio also pursues development programs across mendelian disorders and oncology.
The company generates revenue from product sales and leverages partnerships with major pharmaceutical and research organizations, including Novartis, Bayer, and Stanford University, to fund development efforts. As a biopharmaceutical firm founded in 2015 and based in Palo Alto, California, BridgeBio operates in the rare genetic disease space, where patient populations are small but treatment options limited and unmet medical needs substantial. The company's financial model depends on…
Today's top-scoring strategy for BBIO
Our engine ranks defined-risk strategies on the live BBIO chain by probability of profit and risk/reward, then surfaces the best-scoring one. It is an educational illustration, not advice.
| Action | Qty | Type | Strike | Premium |
|---|---|---|---|---|
| Sell | 1× | CALL | $87.5 | $0.80 |
| Buy | 1× | CALL | $95 | $0.10 |
Simulation
Forward simulation of 6,000 lognormal price paths to expiration — not a historical backtest.
Strategy analysis
Greeks vs price
Price × volatility (today)
| −30% | −15% | IV | +15% | +30% | |
|---|---|---|---|---|---|
| $100 | −$603 | −$570 | −$540 | −$514 | −$491 |
| $96 | −$500 | −$469 | −$445 | −$425 | −$408 |
| $92 | −$341 | −$332 | −$324 | −$318 | −$312 |
| $88 | −$164 | −$182 | −$195 | −$204 | −$211 |
| $84 | −$27 | −$56 | −$81 | −$101 | −$117 |
| $80 | $43 | $22 | $0 | −$21 | −$39 |
| $76 | $66 | $57 | $45 | $30 | $15 |
| $72 | $70 | $68 | $63 | $56 | $47 |
| $68 | $70 | $70 | $69 | $66 | $62 |
| $64 | $70 | $70 | $70 | $69 | $68 |
| $60 | $70 | $70 | $70 | $70 | $70 |
Illustrative example at BBIO's latest available price, computed with the same engine as the tool. Live option fills and the real IV skew refresh during US market hours.
Implied volatility
BBIO is currently trading with moderate implied volatility, broadly in line with other large-cap stocks. On the options we scanned that was around 32% implied volatility, and higher implied volatility means richer premiums and wider expected moves.
Options on BBIO currently price in about 32% implied volatility, versus roughly 52% the stock has actually realised over the past month. That makes options relatively cheap — an edge for strategies that buy premium, such as long calls, long puts and debit spreads.
BBIO's IV Rank is 0/100: implied volatility sits 0% of the way between its 10-day low (32%) and high (61%), and is above 0% of recorded days. Premium is historically cheap, which favours net-debit strategies like long options and debit spreads.
Off that volatility, the options market is pricing a move of about ±$7.86 (±10%) in BBIO by 2026-09-18 — a range of roughly $72.36 to $88.08. Strikes inside that band hold most of the premium and see most of the action.
Across strikes, downside puts on BBIO trade at a higher implied volatility than upside calls — the market is paying up for crash protection. That skew favours selling put spreads or buying calls over symmetric trades.
BBIO insider trading activity (SEC Form 4)
Open-market insider transactions at BBIO over roughly the last six months, from SEC Form 4 filings. Open-market buys are the rarer, more telling signal — routine selling under pre-arranged plans is common, so read a net-selling figure with that in mind.
| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| Apuli Maricel | Sell | 2,000 | $160K | 2026-07-30 |
| Ellis Andrea | Sell | 17,167 | $1.4M | 2026-07-09 |
| Cook Jennifer E. | Sell | 112,422 | $10.1M | 2026-07-09 |
| Cook Jennifer E. | Sell | 36,167 | $3.0M | 2026-07-09 |
| Cook Jennifer E. | Sell | 37,167 | $2.6M | 2026-06-24 |
| Cook Jennifer E. | Sell | 2,196 | $151K | 2026-06-23 |
Source: SEC Form 4 filings via Finnhub. Open-market purchases (P) and sales (S) only — grants, option exercises, gifts and tax withholding are excluded. Informational context, not investment advice.
Earnings & IV crush
BBIO's next earnings report is due around October 28, 2026. Options that expire after it price in a binary move, so their implied volatility is elevated and usually collapses right after the announcement — an "IV crush". If your expiration falls before this date, the trade sidesteps the event.
Key figures
- Market cap
- $16.1B
- Beta (vs market)
- 0.98
- 52-week range
- $42.09–$93.42 (74% up the range)
- Short interest
- 14.7% of float · 5.1 days to cover
With 14.7% of BBIO's float sold short, squeeze and gap risk are elevated — one reason its options can stay expensive.
How to choose an options strategy for BBIO
Start with your outlook on BBIO, then match it to a defined-risk structure. Here are the most common choices and when each makes sense:
Bullish
Buy a call for leverage with capped risk, or a bull call spread to lower the cost and breakeven when you have a target price.
Long Call → Bull Call Spread →Bearish
Buy a put to profit from a decline with defined risk, or a bear put spread to cheapen the trade when you expect a measured move down.
Long Put → Bear Put Spread →Neutral
Sell an iron condor to collect premium while BBIO stays between two strikes, or write a covered call against shares you already own.
Iron Condor → Covered Call →⧉ Embed this free calculator on your site →
How we pick the best strategy
For each ticker we pull the live option chain, build every supported strategy around the at-the-money strikes, and score them on probability of profit, risk/reward and capital efficiency — favouring defined-risk structures where the maximum loss is known up front. Methodology →
Open BBIO in the free calculator →
Frequently asked questions
What is the best options strategy for BBIO?
It depends on your outlook. Bullish traders often use a long call or bull call spread on BBIO; bearish traders a long put or bear put spread; neutral traders an iron condor or covered call. Our live scan above shows the current highest-scoring defined-risk play.
Are BBIO options liquid enough to trade?
BridgeBio Pharma, Inc. (BBIO) is among the most actively-traded US options, which usually means tight bid/ask spreads and plenty of strikes and expirations — though you should always check the open interest and spread on the exact contract.
How much money do I need to trade BBIO options?
Buying a single BBIO call or put can cost as little as the premium (often one to a few hundred dollars), while income strategies like a cash-secured put need enough capital to buy 100 shares if assigned.
Is this financial advice?
No. Everything here is educational and uses delayed, third-party data. It is not a recommendation to trade BBIO or any security. Do your own research.
What does BridgeBio Pharma, Inc. do?
BridgeBio Pharma, Inc. (BBIO) operates in the Biotechnology industry. The "About BridgeBio Pharma, Inc." section above gives a fuller picture of what the company does and how it earns money.
Does BridgeBio Pharma, Inc. pay a dividend?
We don't show a confirmed dividend yield for BridgeBio Pharma, Inc. here, so treat it as uncertain: before writing calls, check its current dividend and ex-dividend date with your broker — an approaching ex-dividend date can trigger early assignment on in-the-money short calls.
When does BridgeBio Pharma, Inc. next report earnings?
BridgeBio Pharma, Inc.'s next earnings are expected around October 28, 2026. Implied volatility usually climbs into the report and drops sharply afterwards (IV crush) — important for any options position held over the date.
Price trend
Tickers related to BBIO
Comparing BBIO with similar names can help you choose the best options strategy:
Company information
- Headquarters
- 3160 Porter Drive, Suite 250, Palo Alto, CA, 94304, United States
- Industry
- Biotechnology
- Employees
- 834
- CEO
- Dr. Neil Kumar Ph.D.
- Phone
- 650 391 9740
- Website
- bridgebio.com
Best Options Strategy by Ticker →
Educational use only. Quotes are delayed ~15 minutes and nothing here is financial advice. Options trading involves substantial risk of loss. Privacy · Terms.